apixaban · Bristol · NDA 220073
Eliquis Sprinkle
Earliest generic entry, as listed
22 May 2041
Blocked by patent: US 11896586 (pediatric extension).
Listed patents · 2 unexpired
4 Orange Book listing rows for 2 patents, including 2 pediatric extensions. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 11896586 | drug product, use U-4180 | 22 May 2041 |
| US 11896586 listing row | drug product, use U-4180 | 22 Nov 2040 |
| US 11896586 listing row | pediatric extension · sets the listed date | 22 May 2041 |
| US 6967208 | drug substance, drug product, use U-4180 | 21 May 2027 |
| US 6967208 listing row | drug substance, drug product, use U-4180 | 21 Nov 2026 |
| US 6967208 listing row | pediatric extension | 21 May 2027 |
Exclusivities · 2 unexpired
| PED | pediatric (6 months added) | 17 Oct 2028 |
| NP | new product | 17 Apr 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 220073 · 001 · RLD | for suspension, oral | 0.15MG | 22 May 2041 |